Moderna Stock Climbs on FDA Emergency Use News

Earlier this month, the company requested full FDA approval for the vaccine in teens

Deputy Editor
Jun 10, 2021 at 10:05 AM
facebook twitter linkedin


Moderna Inc (NASDAQ:MRNA) is back in the spotlight today, after the biotech concern asked the U.S. Food and Drug Administration (FDA) to approve the emergency use of its Covid-19 vaccine mRNA in adolescents ages 12 to 17. On May 25, Moderna said its vaccine was 100% effective in a study of adolescents in that age range -- which included more than 3,700 participants -- and saw no new Covid-19 cases observed after two doses of the vaccine. MRNA is responding well to the news, last seen 1.9% higher to trade at $221.48.

The company made headlines earlier this month after applying for full FDA approval for the vaccine, and the security went on to notch a new record high of $227.71 by June 7. Carving out a channel of higher highs all year, the shares' 10-day moving average has moved in to guide the shares higher in recent months. Now up an impressive 108.6% year-to-date, MRNA is on track for its fourth straight weekly win.

Moderna stock is sporting attractively priced premiums at the moment, too. The stock's Schaeffer's Volatility Index (SVI) of 63% stands higher than just 10% of all other readings from the past year. In simpler terms, option players are pricing in low volatility expectations right now.

What’s more, its Schaeffer's Volatility Scorecard (SVS) sits at a relatively high 81 out of a possible 100, indicating that the stock has managed to exceed these volatility expectations over the last 12 months.

 

Stop leaving money on the table with the same old broken options trading approach...

There is no options strategy that more perfectly capitalizes during earnings season better than this simple call and put buying strategy. Perfect for aggressive traders looking to recover their suffering portfolios so far in 2022. With the simplest possible options strategy, Schaeffer's team with 100+ years of options trading excellence, target 200% gains on every single trade. So many trades are being beaten down by the market, but don't be one of them! Don't waste another second... join us right now before the next trade is released! 

 
Best stocks for October and worst stocks for October
 


 


 
Special Offers from Schaeffer's Trading Partners